association

Full identifier: http://purl.org/np/RAbrhktLY24urNggalkd2XhZsG7deE0eYT9Tfz-fR_6EE#association

Assigned to 1 class:

Minted in Nanopublication

 RAbrhktLY2 comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RAbrhktLY2... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T14:56:16.700+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAbrhktLY2... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RAbrhktLY2... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RAbrhktLY2... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
chronic lymphocytic leukemia cll arzerra ofatumumab is indicated in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate see clinical studies 14 1 in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll see clinical studies 14 2 for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll see clinical studies 14 3 for the treatment of patients with cll refractory to fludarabine and alemtuzumab see clinical studies 14 4 arzerra ofatumumab is a cd2 directed cytolytic monoclonal antibody indicated for the treatment of chronic lymphocytic leukemia cll 1 in combination with chlorambucil for the treatment of previously untreated patients with cll for whom fludarabine based therapy is considered inappropriate in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed cll for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive cll for the treatment of patients with cll refractory to fludarabine and alemtuzumab
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T12:56:16.700Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)